P04.13
Newborn affected by maternal use of anticonvulsants
HCC risk adjustment mapping
CMS-HCC V28
Drug Use Disorder, Moderate/Severe, or Drug Use with Non-Psychotic Complications
Coding notes
Excludes 1 never coded together · Excludes 2 may co-exist
nonteratogenic effects of substances transmitted via placenta
congenital malformations (Q00-Q99) encounter for observation of newborn for suspected diseases and conditions ruled out (Z05.-) neonatal jaundice from excessive hemolysis due to drugs or toxins transmitted from mother (P58.4) newborn in contact with and (suspected) exposures hazardous to health not transmitted via placenta or breast milk (Z77.-)
any current condition in newborn, if applicable
These codes are for use when the listed maternal conditions are specified as the cause of confirmed morbidity or potential morbidity which have their origin in the perinatal period (before birth through the first 28 days after birth).
conditions that have their origin in the fetal or perinatal period (before birth through the first 28 days after birth) even if morbidity occurs later
congenital malformations, deformations and chromosomal abnormalities (Q00-Q99) endocrine, nutritional and metabolic diseases (E00-E88) injury, poisoning and certain other consequences of external causes (S00-T88) neoplasms (C00-D49) tetanus neonatorum (A33)
Codes from this chapter are for use on newborn records only, never on maternal records
Official Guidelines for P04.13
FY 2026 ›Subsections
- I.C.16.aGeneral Perinatal Rules
- I.C.16.bObservation and Evaluation of Newborns for Suspected
- I.C.16.cCoding Additional Perinatal Diagnoses
- I.C.16.dPrematurity and Fetal Growth Retardation
- I.C.16.eLow birth weight and immaturity status
- I.C.16.fBacterial Sepsis of Newborn
- I.C.16.gStillbirth
- I.C.16.hCOVID-19 Infection in Newborn
Find P04.13 in the alphabetic index
1 index path leads to this code